Pro-ADM vs PCT in Patients With Complications Post Hematopoietic Stem Cell Transplantation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-10-20

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective, multicenter, spontaneous, non-interventional, non pharmacological. Study aimed at evaluate kinetics, diagnostic and prognostic value of pro-ADM (proadrenomedullin) as compared to PCT (procalcitonin) in patients presenting with infections or other complications post hematopoietic stem cell transplantation (HSCT)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Role of Immune and Inflammatory Response in Recipients of Allogeneic Haematopoietic Stem Cell Transplantation (SCT) Affected by Severe COVID19

NCT04349540

COVID19

UNKNOWN

Hemostatic Complications in Hematopoietic Stem Cell Transplantation

NCT02281240

Hemostatic Disorders

UNKNOWN

Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation

NCT07349498

Hematopoietic Stem Cell Transplantation Transplant Complication Cardiovascular Events

RECRUITING

Prospective Study of Belated Pulmonary Complications Occurring in Children Treated With Allogeneic Hematopoietic Stem Cells.

NCT02032381

Bone Marrow Transplant Infection Bronchiolitis Obliterans Chronic Respiratory Insufficiency +2 more

COMPLETED NA

Immunomonitoring After Hematopoietic Stem Cell Transplantation

NCT04635397

Hematopoietic Stem Cell Transplantation

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Evaluation of diagnostic performance of pro-ADM as compared to palliative care therapy (PCT) in paediatric and young adult patients with any type of complications after hematopoietic stem cell transplantation or with transplant related complications.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stem Cell Transplant Complications

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Paediatric patients receiving HCTS with infectious complications post HCTS

Paediatric patients receiving allogeneic hematopoietic stem cell transplantation (HCTS) and who present with infectious complications post HSCT or with transplant related complications (acute graft-versus-host disease- GvHD-, sinusoidal obstruction syndrome -SOS-, engraftment-ES- and pre-engraftment syndrome- pre-ES-, graft failure, thrombotic microangiopathy associated with HSCT- TA-TMA or those without complications post HSCT).

observation

Intervention Type OTHER

observation and prospective data collection

Paediatric patients receiving HCTS without infectious complications post HCTS

observation

Intervention Type OTHER

observation and prospective data collection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

observation

observation and prospective data collection

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent of the parents/legal guardians and patient's assent/consent according to national regulations. For subjects who turn 18 years of age during participation in this study, participation in the future use portion of the study after their 18th birthday requires that they sign the informed consent statement following turning 18 years of age.
* Age at time of registration from 28 days to less than 39 years of age.
* Malignant disease (i.e. Acute lymphocytic leukemia (ALL), Acute myeloid leukemia (AML), Myelodysplastic syndromes (MDS)) or nonmalignant disease (e.g. immunodeficiency or inherited disorders of metabolism or hemoglobinopathies etc.) indicated for allogeneic HSCT.

Exclusion Criteria

* Age less than 28 days
* Obese patients with body mass index: \> 30 kg/m\^2.
* Impaired cardiac function: severe cardiac insufficiency indicated by left ventricle ejection fraction (LVEF) ≤ 35%.
* Impaired liver function indicated by Bilirubin \>3 times the upper limit of normal (ULN), or aspartate aminotransferase/alanine aminotransferase (AST/ALT) \>10 times ULN
* Impaired renal function indicated by estimated glomerular filtration rate (GFR), according to the Schwartz formula for ages 1-17 and according to CDKEPI creatinine equation for ages above 17 years old) \< 60 mL/min/1,73m\^2.
* Concurrent severe active infection at the start of conditioning regimen

Minimum Eligible Age

28 Days

Maximum Eligible Age

39 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No